Ultragenyx Pharmaceutical (RARE)

Executive Summary

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. With three marketed products—Crysvita (burosumab) for X-linked hypophosphatemia, Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders, and Mepsevii (vestronidase alfa-vjbk) for Mucopolysaccharidosis VII—the company has established a commercial foundation. Its pipeline comprises 61 drug candidates spanning metabolic, neuromuscular, and endocrine disorders, with late-stage programs in Angelman syndrome, osteogenesis imperfecta, and MPS IIIA. Ultragenyx leverages its expertise in rare disease development to address conditions with high unmet medical need. Key upcoming catalysts include data from the Phase 3 GTX-102 study in Angelman syndrome, which is actively enrolling and expected to report interim or top-line results in late 2026 to 2027. The Phase 2/3 setrusumab trial for osteogenesis imperfecta is also ongoing, with readout anticipated around 2027. Additionally, the Phase 3 adjuvant immunomodulatory therapy for MPS IIIA could provide updates on efficacy and safety. Despite the inherent risks of rare disease development, Ultragenyx's strong commercial base, diverse pipeline, and track record of approvals support a positive outlook. Potential label expansions and regulatory successes could further drive growth.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 GTX-102 interim data in Angelman syndrome55% success
• Q2 2027Phase 2/3 setrusumab top-line results in osteogenesis imperfecta60% success
• Q4 2026Phase 3 adjuvant immunomodulatory therapy update in MPS IIIA45% success